Immunisation with Torpedo acetylcholine receptor.
Acetylcholine mediates the transfer of information between neurons in the electric organ of, for example, Torpedo as well as in vertebrate skeletal muscle. The nicotinic acetylcholine receptor complex translates the binding of acetylcholine into ion permeability changes. This leads to an action potential in the muscle fibre. The nicotinic acetylcholine receptor protein has been purified from Torpedo by use of affinity chromatography. The receptor is an intrinsic membrane glycoprotein composed of five polypeptide chains. When various animals are immunised with the receptor they demonstrate clinical signs of severe muscle weakness coincident with high antibody titres in their sera. The symptoms resemble those found in the autoimmune neuromuscular disease myasthenia gravis in humans. This animal model has constituted a unique model for studying autoimmune diseases. This paper reviews some of the work using Torpedo acetylcholine receptor in order to increase the understanding of the motor nervous system function and myasthenia gravis. It is now known that the nicotinic acetylcholine receptor protein is the antigen involved in myasthenia gravis. The mechanism of immune damage involves a direct block of the receptor function. This depends on the presence of antibodies which crosslink the postsynaptic receptors leading to their degradation. The questions to be answered in the future are; (a) what initiates or triggers the autoimmune response, (b) how do the antibodies cause the symptoms--is there a steric hindrance of the interaction of acetylcholine and the receptor, (c) why is there not a strict relationship between antibody titre and severity of symptoms, and (d) why are some muscles affected and other spared? With help of the experimental model, answers to these questions may result in improved strategies for the treatment of the autoimmune disease myasthenia gravis.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000276:immunology; D000911:Antibodies, Monoclonal; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D055598:Chemical Phenomena; D002621:Chemistry; D004594:Electrophysiology; D007114:Immunization; D007118:Immunoassay / Q000379:methods; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D009045:Motor Endplate / Q000378:metabolism; D009132:Muscles / Q000473:pathology; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009469:Neuromuscular Junction / Q000502:physiology; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D011950:Receptors, Cholinergic / Q000276:immunology*; D011978:Receptors, Nicotinic / Q000276:immunology / Q000302:isolation & purification*; D009435:Synaptic Transmission; D014101:Torpedo / Q000378:metabolism*
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000911:Antibodies, Monoclonal; D007130:Immunoglobulin Idiotypes; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic